Merging Companies Safely

Every life scientist practices due diligence.

Written byWilliam Gaede
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Every life scientist practices due diligence. Whenever working with another group, acquiring the rights to a technology, or entering a round of financing, individuals take steps to make sure that interaction goes smoothly – the very premise underlying due diligence. When those interactions involve intellectual property (IP), the standard due diligence procedure is to execute nondisclosure agreements to protect the confidentiality of the information exchanged. But is this sufficient? If someone overhears intellectually protected information during a transaction, they can't "unlearn" what they now know about a competitor.

There are other unforeseen wrinkles that can further complicate the process. Unwary companies or labs may make missteps during IP due diligence that dissolve the cloak of protection for privileged attorney analyses and opinions on their IP, subjecting that work to discovery in lawsuits. Misunderstandings between parties as to the proper scope of due diligence can arise, ultimately threatening the deal. All ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies